CN102068444B - Ointment for treating skin diseases - Google Patents
Ointment for treating skin diseases Download PDFInfo
- Publication number
- CN102068444B CN102068444B CN2011100099390A CN201110009939A CN102068444B CN 102068444 B CN102068444 B CN 102068444B CN 2011100099390 A CN2011100099390 A CN 2011100099390A CN 201110009939 A CN201110009939 A CN 201110009939A CN 102068444 B CN102068444 B CN 102068444B
- Authority
- CN
- China
- Prior art keywords
- grams
- ointment
- milligrams
- milliliters
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 26
- 208000017520 skin disease Diseases 0.000 title abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 15
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008117 stearic acid Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 4
- 229960000458 allantoin Drugs 0.000 claims abstract description 4
- 229910021538 borax Inorganic materials 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 4
- 210000000481 breast Anatomy 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 claims description 4
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 229960002509 miconazole Drugs 0.000 claims description 3
- -1 miconazole nitrates Chemical class 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 abstract description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 2
- 208000003455 anaphylaxis Diseases 0.000 abstract description 2
- 229960000282 metronidazole Drugs 0.000 abstract description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 abstract description 2
- 229960005040 miconazole nitrate Drugs 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 abstract 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 abstract 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 abstract 1
- 229940053050 neomycin sulfate Drugs 0.000 abstract 1
- 229940126307 triamcinolone acetate Drugs 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 201000009053 Neurodermatitis Diseases 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an ointment for treating skin diseases. 10 grams of ointment is prepared from 10 milligrams of miconazole nitrate, 1 milligram of triamcinolone acetate, 3,000 units of neomycin sulfate, 100 milligrams of metronidazole and 50 milligrams of borneol in the presence of an ointment auxiliary material, wherein the ointment auxiliary material is single emulsion; the single emulsion is a compound preparation and comprises the following components by weight (volume): 35 grams of glycerol monostearate, 130 to 150 grams of stearic acid, 70 grams of albolene, 20 milligrams of azone, 1 grams of ethylparaben, 560 to 580 milliliters of water, 4 grams of borax, 4 grams of lauryl sodium sulfate, 10 to 20 milliliters of triethanolamine, 160 milliliters of glycerol and 3 grams of allantoin. According to the formula, the ointment is used for tens of thousands of patients clinically, the satisfaction of the patients is 100 percent, the ointment does not have special taboos, and an anaphylactic reaction and discomfort do not occur.
Description
Technical field
The present invention relates to the dermopathic ointment of a kind of treatment.
Background technology
Ointment has consequence in treating for skin disease, the body innerlich anwenden is difficult to reach skin surface, and cuticular layer, the squama position.Have only the external emulsifiable paste to add antibiotic, antipruritic, infiltration, chemosmotic medicine, just can play the combination of inner and outside and treat dermopathic purpose.
Summary of the invention
Technical problem to be solved by this invention provides the dermopathic ointment of a kind of treatment.
The present invention adopts technical scheme:
The dermopathic ointment of a kind of treatment is an example to prepare 10 gram ointment: 10 milligrams of miconazole nitrates, and 1 milligram of triamcinolone acetonide acetate, polygynax 3000 units, 100 milligrams of metronidazoles, 50 milligrams of Borneolum Syntheticums are equipped with the ointment adjuvant.
Said ointment adjuvant is single breast, and said single breast is a compound preparation, and the prescription of single breast is: glyceryl monostearate 35 grams, stearic acid 130-150 gram; White vaseline 70 grams, 20 milligrams of azones, ethyl hydroxybenzoate 1 gram; Water 560-580 milliliter, Borax 4 grams, sodium lauryl sulphate 4 grams; Triethanolamine 10-20 milliliter, 160 milliliters of glycerol, allantoin 3 grams.
In inventor's treating skin disease of four more than ten years, summed up the effective medicine for external use of a cover, cured ten hundreds of dermatosis patients.And antifungal drug for oral administration is to liver, kidney, and infringement is big, and is little to the skin surface effect, selects for use medicine for external use safety to have no side effect.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is elaborated.
The dermopathic ointment of a kind of treatment is an example to prepare 10 gram ointment: 10 milligrams of miconazole nitrates, and 1 milligram of triamcinolone acetonide acetate, polygynax 3000 units, 100 milligrams of metronidazoles, 50 milligrams of Borneolum Syntheticums are equipped with the ointment adjuvant.Get final product by this proportional arrangement during large-scale production.
Said ointment adjuvant is single breast, and said single breast is a compound preparation, and the prescription of single breast is: glyceryl monostearate 35 grams, stearic acid 130-150 gram; White vaseline 70 grams, 20 milligrams of azones, ethyl hydroxybenzoate 1 gram; Water 560-580 milliliter, Borax 4 grams, sodium lauryl sulphate 4 grams; Triethanolamine 10-20 milliliter, 160 milliliters of glycerol, allantoin 3 grams.In order to regulate the hardness of ointment, the stearic acid in single Ruzhong, triethanolamine, water, glycerol can suitably increase and decrease as required.
Packing: medicinal round plastic box 10-20 gram.
Pharmaceutical analysis, pharmacological action:
Miconazole nitrate is the broad-spectrum antifungal medicine, and polygynax is effective to multiple Grain-positive and negative bacteria, and metronidazole is effective to various acarids, and triamcinolone acetonide acetate has the effect of antiinflammatory antiallergic and antipruritic, and Borneolum Syntheticum has anticorrosion antipruritic, clearing away heat to alleviate pain, immersional wetting.
Character: be the milky ointment of emulsion-type substrate.
Indication: eczema, dermatitis, tinea corporis, tinea cruris, tinea capitis, acne rosacea, scabies.
Usage and dosage: external, directly wipe in the affected part of cleaning, two to three times on the one
Storage: sealing, preserve (being no more than 20 ℃) in the cool
Two more than ten years of 21 years old trouble skin infection of the big great waves of Mei Yuan town, case 1. Fuping County scape man, various big hospital is failed to respond to any medical treatment, and fully recovers a course of treatment with the treatment of skin bacterium frost emulsifiable paste.(30 days course of treatment)
Five-pointed star village, Po Tou town, case 2. Pucheng County ten thousand religion men suffered from neurodermatitis in 36 years old, with recovery from illness course of treatment of skin bacterium frost emulsifiable paste treatment.
The peaceful town king of case 3. Pucheng County parties is just printing the man and was suffering from tinea cruris, neurodermatitis in 61 years old, with two recoveries from illness course of treatment of skin bacterium frost emulsifiable paste treatment.
Case 4. Weinan City Zhou Zuocheng man suffered from neurodermatitis, acne rosacea for many years in 60 years old, with three recoveries from illness course of treatment of skin bacterium frost emulsifiable paste treatment.
31 years old trouble skin infection of case 5. Baishui County Lei Cun township passage village Li Yuan man fully recovered with the treatment of skin bacterium frost emulsifiable paste for many years a course of treatment.
Above prescription is through the thousands of examples of clinical use, and effect satisfied 100% is effective, does not have special taboo, does not also find anaphylaxis, the thing of discomfort.
Should be understood that, concerning those of ordinary skills, can improve or conversion, and all these improvement and conversion all should belong to the protection domain of accompanying claims of the present invention according to above-mentioned explanation.
Claims (2)
1. the dermopathic ointment of treatment is characterized in that, is example to prepare 10 gram ointment: 10 milligrams of miconazole nitrates, and 1 milligram of triamcinolone acetonide acetate, polygynax 3000 units, 100 milligrams of metronidazoles, 50 milligrams of Borneolum Syntheticums are equipped with the ointment adjuvant.
2. ointment according to claim 1 is characterized in that, said ointment adjuvant is single breast, and said single breast is a compound preparation; The prescription of single breast is: glyceryl monostearate 35 grams, stearic acid 130-150 gram, white vaseline 70 grams, 20 milligrams of azones; Ethyl hydroxybenzoate 1 gram, water 560-580 milliliter, Borax 4 grams, sodium lauryl sulphate 4 grams; Triethanolamine 10-20 milliliter, 160 milliliters of glycerol, allantoin 3 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100099390A CN102068444B (en) | 2011-01-18 | 2011-01-18 | Ointment for treating skin diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100099390A CN102068444B (en) | 2011-01-18 | 2011-01-18 | Ointment for treating skin diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102068444A CN102068444A (en) | 2011-05-25 |
| CN102068444B true CN102068444B (en) | 2012-08-15 |
Family
ID=44027324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100099390A Expired - Fee Related CN102068444B (en) | 2011-01-18 | 2011-01-18 | Ointment for treating skin diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102068444B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920997B (en) * | 2012-11-16 | 2013-08-14 | 徐汝津 | Compound tinea ointment |
| CN103933051B (en) * | 2014-05-12 | 2014-12-24 | 广东台城制药股份有限公司 | Triamcinolone acetonide acetat and preparation method thereof |
| CN105106487A (en) * | 2015-09-24 | 2015-12-02 | 青岛海之源智能技术有限公司 | Metronidazole and miconazole nitrate compound ointment and method for preparing same |
| CN105497043B (en) * | 2015-12-18 | 2019-01-18 | 汶上县皮肤病防治站 | A kind of externally applied drug and preparation method thereof for treating skin eczema and eczema-like dermatitis |
| CN106074572A (en) * | 2016-08-09 | 2016-11-09 | 梁东荣 | One treats dermopathic medicine and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324607A (en) * | 2000-03-27 | 2001-12-05 | 塔罗制药工业有限公司 | Anti-fungus agent for local treatment of fungus infection of finger and its peripheral tissue and controllable releasable system of keratin-dissolving agnt |
| CN1706365A (en) * | 2005-05-09 | 2005-12-14 | 凌沛学 | Reversible thermal gelation aqueous pharmaceutical composition |
-
2011
- 2011-01-18 CN CN2011100099390A patent/CN102068444B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324607A (en) * | 2000-03-27 | 2001-12-05 | 塔罗制药工业有限公司 | Anti-fungus agent for local treatment of fungus infection of finger and its peripheral tissue and controllable releasable system of keratin-dissolving agnt |
| CN1706365A (en) * | 2005-05-09 | 2005-12-14 | 凌沛学 | Reversible thermal gelation aqueous pharmaceutical composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102068444A (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068444B (en) | Ointment for treating skin diseases | |
| Phillips | Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories | |
| CN101590107B (en) | Rhinitis ointment | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN101214254B (en) | New use of mangiferin compounds | |
| CN108853003A (en) | A kind of Nifuratel-Nysfungin soft-capsule type suppository and preparation method thereof | |
| CN103157050B (en) | Traditional Chinese medicine composition for treating vulvar itching diseases and preparation method thereof | |
| CN102000093A (en) | External ointment for treating impetigo | |
| CN101371899B (en) | Medicine for treating tympanitis | |
| CN111743910A (en) | Application of baicalin in the preparation of medicines for improving diabetic lung injury | |
| CN101433518A (en) | Compound ofloxacin injection for animals | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN102309631A (en) | Specific poultice for ringworm sores | |
| CN102485239A (en) | Chinese herbal composition used for treating gynecological inflammation | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN101380328A (en) | Medicine for treating coryza and its preparation method | |
| Onwuchekwa et al. | Anti-gastric ulcer and antiinflammatory properties of betulinic acid in male albino rats | |
| CN101843626A (en) | Tincture for treating acne | |
| CN100352467C (en) | Chinese medicinal composition for treating upper respiratory tract infection | |
| CN100352449C (en) | Medicament composition for treating tinea pedis and tinea corporis | |
| CN111481548A (en) | Application of 4- (2, 6-dichlorobenzyloxy) -3- (3-aminopyridine) benzo [ d ] isoxazole in pharmacy | |
| CN1451387A (en) | Scutellaria root extract nose preparation | |
| CN100488520C (en) | Medicine for curing allergic colitis | |
| CN101933978A (en) | Liquid medicine for treating beriberi and tinea manus and pedis | |
| CN1301727C (en) | Externally applied Chinese medicine preparation for treating skin disease and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120815 Termination date: 20130118 |